Literature DB >> 2022495

Immunogenetics of human American cutaneous leishmaniasis. Study of HLA haplotypes in 24 families from Venezuela.

M L Lara1, Z Layrisse, J V Scorza, E Garcia, Z Stoikow, J Granados, W Bias.   

Abstract

Twenty-four families with one or multiple cases of localized cutaneous leishmaniasis (LCL) from an endemic region with the highest incidence of LCL in Venezuela were typed from HLA-ABC, DR, DQ antigens and complement factors. The parental HLA haplotypes segregated at random among healthy and affected siblings but in backcross families significantly higher frequencies of HLA-A28 (p = 0.0018), -Bw22 (p = 0.0122), or -DQw8 (p = 0.0364) were present in affected compared to healthy siblings. HLA-B15 showed a higher frequency (p = 0.0062) among the latter group. Haplotypes Bw22CF31 (p = 0.0076) and Bw22DRw11DQw7 (p = 0.0163) were also significantly more frequent in affected compared to healthy siblings and A2Cw- (p = 0.0445) among the latter. No HLA genetic linkage with a putative LCL susceptibility gene(s) could be demonstrated in this study. A case/control comparison of 26 unrelated LCL patients (one proband from each family) and healthy individuals of the same ethnic origin confirmed the association of HLA-Bw22 (pc = 0.048) and -DQw3 (pc = 0.036) with LCL. The relative risk reached 12.5 for Bw22 and 4.25 for DQw3 with ethiologic factors of 0.17 and 0.64, respectively. HLA-DQw3 apparently makes the major contribution as a genetic risk factor for LCL at the population level.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2022495     DOI: 10.1016/0198-8859(91)90081-j

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  19 in total

Review 1.  Science, medicine, and the future: Leishmaniasis.

Authors:  L J Roberts; E Handman; S J Foote
Journal:  BMJ       Date:  2000-09-30

Review 2.  Leishmaniasis: current status of vaccine development.

Authors:  E Handman
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

3.  Evidence for a major gene controlling susceptibility to tegumentary leishmaniasis in a recently exposed Bolivian population.

Authors:  A Alcaïs; L Abel; C David; M E Torrez; P Flandre; J P Dedet
Journal:  Am J Hum Genet       Date:  1997-10       Impact factor: 11.025

4.  Susceptibility to visceral leishmaniasis in the domestic dog is associated with MHC class II polymorphism.

Authors:  Rupert J Quinnell; Lorna J Kennedy; Annette Barnes; Orin Courtenay; Christopher Dye; Lourdes M Garcez; Marie-Anne Shaw; Stuart D Carter; Wendy Thomson; William E R Ollier
Journal:  Immunogenetics       Date:  2003-03-20       Impact factor: 2.846

5.  Cutaneous leishmaniasis in the Peruvian Andes: an epidemiological study of infection and immunity.

Authors:  C R Davies; E A Llanos-Cuentas; S D Pyke; C Dye
Journal:  Epidemiol Infect       Date:  1995-04       Impact factor: 2.451

6.  A major susceptibility locus on chromosome 22q12 plays a critical role in the control of kala-azar.

Authors:  Bruno Bucheton; Laurent Abel; Sayda El-Safi; Musa M Kheir; Sylvana Pavek; Arnaud Lemainque; Alain J Dessein
Journal:  Am J Hum Genet       Date:  2003-10-13       Impact factor: 11.025

7.  Human genetic susceptibility and infection with Leishmania peruviana.

Authors:  M A Shaw; C R Davies; E A Llanos-Cuentas; A Collins
Journal:  Am J Hum Genet       Date:  1995-11       Impact factor: 11.025

Review 8.  Leishmania RNA virus: when the host pays the toll.

Authors:  Mary-Anne Hartley; Catherine Ronet; Haroun Zangger; Stephen M Beverley; Nicolas Fasel
Journal:  Front Cell Infect Microbiol       Date:  2012-07-12       Impact factor: 5.293

9.  Sphingolipid degradation in Leishmania (Leishmania) amazonensis.

Authors:  Agiesh Balakrishna Pillai; Wei Xu; Ou Zhang; Kai Zhang
Journal:  PLoS Negl Trop Dis       Date:  2012-12-20

10.  Association between HLA genes and American cutaneous leishmaniasis in endemic regions of Southern Brazil.

Authors:  Rejane C Ribas-Silva; Adriana D Ribas; Maria C G Dos Santos; Waldir V da Silva; Maria V C Lonardoni; Sueli D Borelli; Thaís G V Silveira
Journal:  BMC Infect Dis       Date:  2013-05-02       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.